Ann Integrative Oncol | Volume 1, Issue 1 | Research Article | Open Access

Neuroendocrine Carcinoma of the Breast: Epidemic, Clinicopathological Features and Treatment

Thi Hong Phan D, Anh Nguyen K. Duc Hong PT

Department of Medicine, University of Medicine Pham Ngoc Thach, Duong Quang Trung Street, District 10, Ho Chi Minh City, Vietnam.

*Correspondance to: Duc Thi Hong Phan 

Fulltext PDF

Abstract

Purpose: To evaluate the clinical and pathologic features and treatment of neuroendocrine carcinoma of the breast. Patients and Method: This is a case series study on 10 patients diagnosed with neuroendocrine breast cancer carcinoma and treated from 1/1/2015 to 30/06/2016 at HCMC Oncology Hospital. Results: The median age is 50 (range 24 to 59). The median duration of disease awareness before hospitalization was 14 weeks (range 2 to 52 weeks). One patient has her history of breast cancer, 1 patient has family history of breast cancer (her aunt). 90 percent of cases presented with a palpable mass of the breast, 10% of cases presented with nipple hemorrhage. Two cases had breast cancer in both sides, 2 cases had 2 lesions in the breast. Median tumor size at hospitalization was 3 cm, 2 cm (range 1 cm to 10 cm). 100% of cases were neuroendocrine carcinoma of the breast and 75% of cases were grad 2. On biological subgroup analysis, we found that 10% of cases were triple negative, 5% of cases were HER2 positive and 65% of patients had high Ki67 levels (>10%). 90% of patients received surgery initially. Taxane-based adjuvant or neoadjuvant chemotherapy was indicated for 50% of patients, but none of them received trastuzumab. We couldn’t evaluate overall survival of the whole group because of the limitation of time. Conclusion: The incidence of neuroendocrine carcinoma of the breast is very rare. The biological nature of invasive breast cancer of this group is usually nonaggressive. Diagnostic delay >3 months is considered an adverse prognostic factor in our series. In general, the treatment for this group of patients is not different from other subtypes.  Patients of this group need to be indicated targeted therapy if possible.

Keywords:

Breast cancer; Neuroendocrine carcinoma; Prognosis; NECB 

Citation:

Thi Hong Phan D, Anh Nguyen K. Duc Hong PT, Department of Medicine, University of Medicine Pham Ngoc Thach, Duong Quang Trung Street, District 10, Ho Chi Minh City, Vietnam. Ann Integr Oncol. 2020; 1(1): 1001..

Subscribe to Our Newsletter